Sign In
Buy LPTX
$0.690
+0 (+0%)
At Close: Jun 23, 2026
Leap Therapeutics Reports First Quarter 2021 Financial Results
08:00am, Friday, 14'th May 2021
CAMBRIDGE, Mass., May 14, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial
Leap Therapeutics and Flagship Biosciences Develop Image Analysis RNAscope Assay for Prospective Trial Enrollment
08:00am, Wednesday, 12'th May 2021
CAMBRIDGE, Mass. and WESTMINSTER, Colo.
LPTX Stock: Over 2.5% Increase Pre-Market Explanation
08:25am, Monday, 12'th Apr 2021
The stock price of Leap Therapeutics Inc (NASDAQ: LPTX) increased by over 2.5% pre-market. This is why it happened.
CAMBRIDGE, Mass., April 1, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the comp
LPTX Stock Price Increases Over 25% Pre-Market: Why It Happened
06:54am, Monday, 22'nd Mar 2021
The stock price of Leap Therapeutics Inc (NASDAQ: LPTX) increased by over 25% pre-market. This is why it happened.
Leap Therapeutics Presents DKN-01 Clinical Data at the Society of Gynecologic Oncology 2021 Annual Meeting on Women's Cancer
06:00am, Monday, 22'nd Mar 2021
CAMBRIDGE, Mass., March 22, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the pre
Leap Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
07:00am, Friday, 12'th Mar 2021
CAMBRIDGE, Mass., March 12, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financi
Leap Therapeutics Announces Publication of DKN-01 Mechanism of Action Data in Molecular Cancer Research
10:17am, Tuesday, 22'nd Dec 2020
CAMBRIDGE, Mass., Dec. 22, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the publ
Leap Therapeutics Presents DKN-01 Monotherapy Data at AACR Virtual Special Endometrial Cancer Conference
09:30am, Monday, 09'th Nov 2020
CAMBRIDGE, Mass., Nov. 9, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the prese
Week 46 MDA Breakout Forecast - November: Short-Term Picks To Give You An Edge
11:56am, Saturday, 07'th Nov 2020
Two new breakout stocks for Week 46 with better than 10% short-term upside potential. This past week three out of four stocks gained more than 10% closing with gains to Friday with AVNS +8.54%, IMVT +
Leap Therapeutics Reports Second Quarter 2020 Financial Results
11:00am, Thursday, 13'th Aug 2020
Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the second quarter ended June 30, 2
Leap Therapeutics Inc (NASDAQ:LPTX) Receives $5.50 Average Target Price from Brokerages
06:44am, Monday, 27'th Jul 2020
Shares of Leap Therapeutics Inc (NASDAQ:LPTX) have earned an average rating of “Buy” from the seven analysts that are currently covering the company, MarketBeat.com reports. One equities research
3 “Strong Buy” Healthcare Stocks Under $5 That Could Double (Or More)
07:30pm, Monday, 20'th Jul 2020
The healthcare sector took its place among the winners this year, rising 21%, compared to the S&P 500’s 0.5% growth. The bottom-line for investors? Wall Street’s focus is on the healthcare space,
Merck KGaA (OTCMKTS:MKGAF) vs. Amarin (OTCMKTS:AMRN) Head-To-Head Contrast
02:52am, Wednesday, 01'st Jul 2020
Amarin (NASDAQ:AMRN) and Merck KGaA (OTCMKTS:MKGAF) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst rec
Benzinga's Top Upgrades, Downgrades For June 29, 2020
02:04pm, Monday, 29'th Jun 2020
Upgrades * SunTrust Robinson Humphrey changed the rating for CoreLogic Inc (NYSE: CLGX) from Hold to Buy. In the first quarter, CoreLogic showed an EPS of $0.76, compared to $0.45 from the year-ago
